1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst @themotleyfool #stocks $APLS $ALPMY
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.…
27,180€
2,07%
Echtzeit-Aktienkurs Apellis Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Apellis Pharmaceuticals Inc. Aktie
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.…
Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN
· Statistically significant 68% (p…
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
WALTHAM, Mass., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that…
Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations…
Apellis Aktie: Leichter Anstieg trotz Jahresverlust
Die Apellis Pharmaceuticals Aktie verzeichnete am 12. Oktober 2024 einen leichten Anstieg von 0,08% auf 24,64 EUR. Trotz dieses minimalen…
Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion
…
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
WALTHAM, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee…
Apellis Pharmaceuticals shares surge after study results By Investing.com
Apellis Pharmaceuticals shares surge after study results…
Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN
· Met the primary endpoint, achieving statistically significant 68% (p…
Apellis Pharmaceuticals, Inc. (APLS) Q2 2024 Earnings Call Transcript
…
Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress
· Rapid reduction in disease activity seen at 12 weeks sustained at one year
· 55% of patients showed…
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
WALTHAM, Mass. and STOCKHOLM, Sweden, May 24, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI)…
Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations…
Apellis Pharmaceuticals enters into senior secured credit facility
…
Earnings call: Apellis Pharmaceuticals Q1 2024 financials show growth By Investing.com
Earnings call: Apellis Pharmaceuticals Q1 2024 financials show growth…
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will…
Apellis Pharmaceuticals stock falls following Mizuho comments, price target cut By Investing.com
Apellis Pharmaceuticals stock falls following Mizuho comments, price target cut…
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the European…
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will…
Apellis Pharmaceuticals director sells over $1 million in company stock By Investing.com
Apellis Pharmaceuticals director sells over $1 million in company stock…
Apellis Pharmaceuticals officer sells $564k in company stock By Investing.com
Apellis Pharmaceuticals officer sells $564k in company stock…
Apellis Pharmaceuticals VP sells over $10k in company stock By Investing.com
Apellis Pharmaceuticals VP sells over $10k in company stock…
Investigation Alert Driven Brands Holdings, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations…
UBS raises Apellis Pharmaceuticals shares target on strong outlook By Investing.com
UBS raises Apellis Pharmaceuticals shares target on strong outlook…
Apellis Pharmaceuticals, Inc. (APLS) Q4 and Full Year 2023 Earnings Call Transcript
…
Apellis Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
…
Apellis Pharmaceuticals Q4 2023 Earnings Preview
…
Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain
…
Apellis Pharmaceuticals upgraded to buy by Jefferies By Investing.com
Apellis Pharmaceuticals upgraded to buy by Jefferies…
Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
SAN DIEGO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) …
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will…
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
WALTHAM, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will…
Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) …
Apellis Pharmaceuticals expects European regulators to reject eye disease drug
Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares fell more than 22% after it said it expects European regulators to reject its therapeutic…
Apellis Pharmaceuticals stock just tumbled. Here’s why By Investing.com
© Reuters. Apellis Pharmaceuticals (APLS) stock just tumbled. Here’s why Apellis Pharma (APLS) stock experienced a sharp pre-market decline following…
Apellis Pharmaceuticals’ stock slides 14% after company gets negative trend vote for eye treatment in Europe
…
: Apellis Pharmaceuticals’ stock slides 14% after company gets negative trend vote for eye treatment in Europe
Apellis Pharmaceuticals Inc.’s stock APLS tumbled 14% early Thursday, after the company said it’s been informed of a negative trend…
Apellis Pharmaceuticals stock just tumbled. Heres why By Investing.com
Apellis Pharmaceuticals stock just tumbled. Heres why…
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
WALTHAM, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi today presented post…
Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)…
Apellis Pharmaceuticals: Focus Shifts Toward Market Share After Apparent Safety Resolution
…
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that the company will…
Apellis Pharmaceuticals tumbles as Citron Research says legal action seems imminent By Investing.com
Apellis Pharmaceuticals tumbles as Citron Research says legal action seems imminent…
APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript
…
Apellis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation
…
Apellis Pharmaceuticals Q3 2023 Earnings Preview
…
Investigation Alert Apellis Pharmaceuticals, KeyCorp, RTX Corporation, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) …
Apellis Pharmaceuticals: Looking For Entry Around Crucial Q3 Earnings
…